NGL Fine Chem Ltd
₹2901.30
(0.81%)
Tue, 13 Oct 2026, 10:36 pm
Health Technology
Pharmaceuticals: Major
24.5KNGL Fine Chem Ratios
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 2.21 | 4.34 | 3.43 | 7.08 | 3.25 | 3.37 | 5.35 | 12.26 | 15.93 | 20.15 | 14.42 | 18.78 | 16.70 | 24.24 | 36.08 | 31.25 | 32.59 |
| Price to book ratio | 0.40 | 0.86 | 0.52 | 0.43 | 0.47 | 0.62 | 1.36 | 3.16 | 3.99 | 3.52 | 3.15 | 1.58 | 6.13 | 5.95 | 3.32 | 4.92 | 2.44 |
| Price to sales ratio | 0.18 | 0.42 | 0.24 | 0.21 | 0.17 | 0.19 | 0.52 | 1.47 | 2.47 | 2.29 | 1.92 | 1.05 | 3.67 | 3.81 | 2.66 | 3.81 | 1.87 |
| Price to cash flow ratio | 0 | 7.98 | 2.06 | 4.85 | 171.79 | 95.14 | 4.80 | 14.54 | 25.20 | 12.07 | 43.07 | 8.48 | 36.83 | 94.45 | 21.15 | 63.96 | 20.06 |
| Enterprise value | 7.38Cr | 15.75Cr | 13.78Cr | 16.84Cr | 21.25Cr | 30.8Cr | 53.83Cr | 149Cr | 252Cr | 270Cr | 306Cr | 171Cr | 930Cr | 1210Cr | 719Cr | 1270Cr | 700Cr |
| Enterprise value to EBITDA ratio | 1.78 | 3.13 | 2.84 | 4.98 | 3.05 | 2.86 | 4.15 | 6.78 | 11.57 | 14.34 | 9.22 | 8.87 | 10.98 | 17.74 | 20.58 | 23.63 | 20.07 |
| Debt to equity ratio | 0.38 | 0.37 | 0.39 | 0.60 | 0.67 | 0.68 | 0.40 | 0.33 | 0.38 | 0.37 | 0.29 | 0.29 | 0.11 | 0.15 | 0.15 | 0.13 | 0.27 |
| Return on equity % | 0 | 22 | 16.26 | 6.31 | 15.67 | 20.33 | 29.04 | 29.59 | 28.73 | 19.29 | 24.52 | 8.72 | 44.76 | 27.90 | 9.63 | 17.03 | 7.75 |
NGL Fine Chem Ltd Ratios
The NGL Fine Chem Ltd Ratios page provides a complete fundamental analysis of NGL Fine Chem Ltd using key valuation, profitability, and financial strength metrics. Investors tracking NGL Fine Chem Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
NGL Fine Chem Ltd (NSE: NGLFINE, BSE: 524774) is currently trading at ₹2901.30, with a market capitalization of ₹1807.47Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, NGL Fine Chem Ltd remains a key stock for fundamental analysis using NGL Fine Chem Ltd Ratios.
NGL Fine Chem Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The NGL Fine Chem Ltd P/E ratio currently stands at 32.59, making it one of the most tracked metrics in NGL Fine Chem Ltd Ratios.
Historically, the NGL Fine Chem Ltd P/E ratio has shown strong fluctuations:
- 2024: 32.59
- 2023: 31.25
- 2022: 36.08
- 2021: 24.24
- 2020: 16.70
The rising NGL Fine Chem Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The NGL Fine Chem Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.44.
Historical P/B trend:
- 2024: 2.44
- 2023: 4.92
- 2022: 3.32
- 2021: 5.95
NGL Fine Chem Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The NGL Fine Chem Ltd P/S ratio currently stands at 1.87, an important part of NGL Fine Chem Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.87
- 2023: 3.81
- 2022: 2.66
- 2021: 3.81
A stable or declining NGL Fine Chem Ltd P/S ratio indicates cautious market sentiment.
NGL Fine Chem Ltd Price to Cash Flow Ratio (P/CF)
The NGL Fine Chem Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.06.
Historical NGL Fine Chem Ltd Price to Cash Flow Ratio:
- 2024: 20.06
- 2023: 63.96
- 2022: 21.15
- 2021: 94.45
- 2020: 36.83
The declining NGL Fine Chem Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
NGL Fine Chem Ltd Enterprise Value Ratios
Enterprise Value (EV)
The NGL Fine Chem Ltd EV currently stands at ₹700Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 700Cr
- 2023: 1270Cr
- 2022: 719Cr
- 2021: 1210Cr
NGL Fine Chem Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The NGL Fine Chem Ltd EV/EBITDA ratio is currently 20.07, a key metric in NGL Fine Chem Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 20.07
- 2023: 23.63
- 2022: 20.58
- 2021: 17.74
Stable NGL Fine Chem Ltd EV/EBITDA indicates balanced valuation.
NGL Fine Chem Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The NGL Fine Chem Ltd D/E ratio is currently 0.27, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.27
- 2023: 0.13
- 2022: 0.15
- 2021: 0.15
NGL Fine Chem Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The NGL Fine Chem Ltd ROE currently stands at 7.75%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 7.75
- 2023: 17.03
- 2022: 9.63
- 2021: 27.90
Declining ROE indicates pressure on profitability.
NGL Fine Chem Ltd Ratios Analysis Summary
The NGL Fine Chem Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether NGL Fine Chem Ltd stock is undervalued, fairly valued, or overvalued.
Tracking NGL Fine Chem Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
